Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise boost the brain benefits of Ozempic-Style drugs?

NCT ID NCT07833813

NEW Disease control Sponsor: University of Regina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Researchers are studying adults with type 2 diabetes who start incretin-mimetic therapy, drugs like semaglutide or tirzepatide. Half the participants also join a 24-week structured exercise program with supervised and home sessions. The trial measures changes in insulin resistance, brain function, gut bacteria, and fitness to see whether exercise adds benefits beyond the medication alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
incretin-mimetic drugs such as semaglutide or tirzepatide, combined with a structured exercise program
What this could lead to
If adding exercise helps, doctors could pair incretin drugs with a tailored workout plan to better protect brain and metabolic health in people with type 2 diabetes.
What could go wrong
The trial is small and runs for only 24 weeks, so any brain or gut benefits may be modest or fade. Exercise programs are hard for some people to stick with, and incretin drugs can cause nausea and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults aged 18 years or older * diagnosed with pre diabetes or type 2 diabetes * prescribed incretin-based therapy (e.g., semaglutide or tirzepatide) * able and willing to participate in the study assessments and, if randomized to the exercise group, the 24-week structured exercise program * able to provide informed consent Exclusion Criteria: * current use of incretin-based therapy outside the study-defined enrollment window * pregnant or planning to become pregnant during the study period * any other medical condition or circumstance that, in the opinion of the research team, would interfere with safe participation or completion of study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre for Kinesiology

    Regina, Saskatchewan, S4S 0A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.